| Previous close | 6.85 |
| Open | 6.85 |
| Bid | 7.00 x 0 |
| Ask | 7.15 x 0 |
| Day's range | 6.85 - 6.85 |
| 52-week range | 6.60 - 11.90 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireEVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Variant Bio, Inc. today announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis.
Simply Wall St.Evotec (ETR:EVT shareholders incur further losses as stock declines 3.7% this week, taking three-year losses to 59%
Investing in stocks inevitably means buying into some companies that perform poorly. But the long term shareholders of...
- Reuters
UPDATE 1-Evotec says it promptly reported share trades withheld by former CEO
German biotech firm Evotec on Monday said it had immediately reported trades in its shares by its former CEO as soon as it was informed of the transactions that he had kept under wraps for up to three years. "Evotec has acted always in compliance with the statutory regulations and our own very strict compliance code," supervisory board Chair Iris Loew Friedrich said in an analyst call. Evotec, which works in drug development with partners including Novo Nordisk, Bayer and Bristol-Myers Squibb, said on Jan. 3 that CEO Werner Lanthaler would resign for personal reasons after almost 15 years with the company.
